The first domestic patent nullity of Humira will stimulate biosimilar development

One of domestic patents of Humira(Abbvie), a TNF-Alpha inhibitor used mainly in rheumatoid arthritis treatment, has been ruled to be nullified.

Thus, biosimilar development of domestic pharmaceutical companies, such as Samsung Bioepis, LG Life Sciences and Celltrion, is expected to be triggered.

According to the industry concerned on the 17^th, the Intellectual Property Tribunal accepted a cla...